Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort

BACKGROUND: Cabazitaxel is a treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel failure. The FUJI cohort aimed to confirm the real-life overall and progression-free survival (OS, PFS) and safety of cabazitaxel. METHODS: Multicentre, non-interventional cohort of Fren...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Cancer
Glavni autori: Rouyer, Magali, Oudard, Stéphane, Joly, Florence, Fizazi, Karim, Tubach, Florence, Jove, Jérémy, Lacueille, Clémentine, Lamarque, Stéphanie, Guiard, Estelle, Balestra, Aurélie, Droz-Perroteau, Cécile, Fourrier-Reglat, Annie, Moore, Nicholas
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964680/
https://ncbi.nlm.nih.gov/pubmed/31719685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0611-6
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items